studied 53 patients with RR B-ALL followed by CD19 CAR-T cell therapy and suggested that the absence of leukemia clone of IGH by HTS 3 weeks after CAR-T cell infusion in patients with MRD-negative CR is associated with improved EFS and OS (20). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.